At the Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy program at the Johns Hopkins Heart and Vascular Institute, we are committed to finding a cure for ARVD / ARVC. This condition is a leading cause of sudden death among young athletes, although the condition can affect people of all ages and activity levels. Approximately one out of every 5,000 individuals is diagnosed with ARVD / ARVC.
ARVD / ARVC was first described in 1982, and may also be known as Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). At Johns Hopkins, we work with national and international teams to care for patients and conduct research.
We have a team of experts dedicated to ARVD/C patients and their families. Meet the team.
Are you seeking treatment for ARVD/C? Contact us.
We have several research programs for ARVD/C patients and their families. Find a program.